Alpha-Synuclein Structure & Function

α-Synuclein is an integral component of Lewy bodies which are comprised of protein clumps and are a pathological hallmark of Parkinson’s disease. Here is the latest research on α-synuclein structure and function.

January 11, 2022

Molecular Tuning of the Nano-Bio Interface: Alpha-Synuclein's Surface Targeting with Doped Carbon Nanostructures.

ACS Applied Bio Materials
Ehsan AlimohammadiNima Rezaei
December 24, 2021
Preprint
Open Access

Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson's disease

MedRxiv : the Preprint Server for Health Sciences
G. M. RiboldiTowfique Raj
December 23, 2021
Preprint
Open Access

Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis

BioRxiv : the Preprint Server for Biology
Bryan A KillingerY. Chu
December 22, 2021

Common sequence motifs of nascent chains engage the ribosome surface and trigger factor.

Proceedings of the National Academy of Sciences of the United States of America
Annika DeckertJohn Christodoulou
December 16, 2021
Open Access

Missense Mutations Modify the Conformational Ensemble of the α-Synuclein Monomer Which Exhibits a Two-Phase Characteristic.

Frontiers in Molecular Biosciences
Adrien GuzzoPatrick Senet
November 28, 2021
Open Access

(De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants.

International Journal of Molecular Sciences
Joana Angélica LoureiroMaria Carmo Pereira
November 28, 2021
Open Access

Polymorphism of Alpha-Synuclein Amyloid Fibrils Depends on Ionic Strength and Protein Concentration.

International Journal of Molecular Sciences
Mantas ZiaunysVytautas Smirnovas
November 14, 2021
Open Access

The Bacterial Amyloids Phenol Soluble Modulins from Staphylococcus aureus Catalyze Alpha-Synuclein Aggregation.

International Journal of Molecular Sciences
Caroline HaikalJia-Yi Li
November 11, 2021
Review

Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.

Glycoconjugate Journal
Inka BrockhausenJennifer Brockhausen
November 9, 2021
Open Access

A Quantitative Perspective of Alpha-Synuclein Dynamics - Why Numbers Matter.

Frontiers in Synaptic Neuroscience
Christian G Specht
November 4, 2021
Preprint
Open Access

Controlled and Selective Photo-oxidation of Amyloid-β Fibrils by Oligomeric p-Phenylene Ethynylenes

BioRxiv : the Preprint Server for Biology
A. M. FanniEva Y Chi
November 4, 2021
Review
Open Access

Alpha-Synuclein Aggregation in Parkinson's Disease.

Frontiers in Medicine
E SrinivasanP S Srikumar
November 4, 2021
Open Access

Interplay between epigallocatechin-3-gallate and ionic strength during amyloid aggregation.

PeerJ
Mantas ZiaunysVytautas Smirnovas
November 3, 2021
Review
Open Access

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.

Acta Pharmaceutica Sinica. B
Kai ZhangBo Liu
October 22, 2021

2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors.

ACS Medicinal Chemistry Letters
Henri T PätsiErik A A Wallén
October 21, 2021

Similarity of the non-amyloid-β component and C-terminal tail of monomeric and tetrameric alpha-synuclein with 14-3-3 sigma.

Computational and Structural Biotechnology Journal
Sarah R EvansJudith Klein-Seetharaman
October 17, 2021

Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease.

Neuropharmacology
Mir Hilal AhmadAmal Chandra Mondal

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved
/feed-previews/alpha-synuclein-structure-and-function/a14f65a7-3296-44da-b665-d4480898b4bc